The Michael Glickman Lab
We are broadly interested in the biology of mycobacteria, which include the major human pathogen M. tuberculosis, the nonpathogenic model organism M. smegmatis, and the cancer biotherapeutic agent BCG.
A multilayered repair system protects the mycobacterial chromosome from endogenous and antibiotic-induced oxidative damage. Dupuy P, Howlader M, Glickman MS. Proc Natl Acad Sci U S A. 2020 Aug 11;117(32):19517-19527. doi: 10.1073/pnas.2006792117. Epub 2020 Jul 29. PMID: 32727901
Bacterial immunotherapy for cancer induces CD4-dependent tumor-specific immunity through tumor-intrinsic interferon-γ signaling. Antonelli AC, Binyamin A, Hohl TM, Glickman MS, Redelman-Sidi G. Proc Natl Acad Sci U S A. 2020 Aug 4;117(31):18627-18637. doi: 10.1073/pnas.2004421117. Epub 2020 Jul 17. PMID: 32680964
Mycobacterial Mutagenesis and Drug Resistance Are Controlled by Phosphorylation- and Cardiolipin-Mediated Inhibition of the RecA Coprotease. Wipperman MF, Heaton BE, Nautiyal A, Adefisayo O, Evans H, Gupta R, van Ditmarsch D, Soni R, Hendrickson R, Johnson J, Krogan N, Glickman MS. Mol Cell. 2018 Oct 4;72(1):152-161.e7. doi: 10.1016/j.molcel.2018.07.037. Epub 2018 Aug 30. PMID: 30174294
Two Accessory Proteins Govern MmpL3 Mycolic Acid Transport in Mycobacteria.Fay A, Czudnochowski N, Rock JM, Johnson JR, Krogan NJ, Rosenberg O, Glickman MS. mBio. 2019 Jun 25;10(3):e00850-19. doi: 10.1128/mBio.00850-19.
The Canonical Wnt Pathway Drives Macropinocytosis in Cancer. Redelman-Sidi G, Binyamin A, Gaeta I, Palm W, Thompson CB, Romesser PB, Lowe SW, Bagul M, Doench JG, Root DE, Glickman MS. Cancer Res. 2018 Aug 15;78(16):4658-4670. doi: 10.1158/0008-5472.CAN-17-3199. Epub 2018 Jun 5.
Michael S. Glickman, MD
- Physician-scientist Michael Glickman investigates the physiology and pathogenic mechanisms of mycobacteria, including regulated intramembrane proteolysis (the Rip1 pathway); double-strand-break repair and associated DNA damage responses; and cell envelope biosynthesis.
- MD, Columbia University College of Physicians and Surgeons
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Michael S. Glickman discloses the following relationships and financial interests:
Ownership / Equity Interests; Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.